Translation. Region: Russian Federation –
Source: People's Republic of China in Russian – People's Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People's Republic of China – State Council News
BEIJING, Nov. 17 (Xinhua) — German healthcare and agribusiness giant Bayer opened its first innovation center in China on Saturday.
As a key component of Bayer's "In China, for the World" strategy, the Bayer E-Town Open Innovation Center in Beijing will incubate local innovative biopharmaceutical companies, support the globalization of medicines developed in China, and collaborate with leading academic and clinical research institutions.
"The opening of the Bayer E-Town Open Innovation Center is a true milestone in our long-term commitment to innovation in China. We have long considered China a strong driver of innovation and part of our global strategy. This center will serve both as a bridge to global research and development and as a local accelerator for the innovation we can find in Beijing and Greater China," said Anastasia Hager, Senior Vice President, Research and Development, and Head of Pharmaceuticals Research at Bayer Pharmaceuticals.
According to A. Hager, China is becoming increasingly powerful thanks to the interconnectedness between academia, startups, and hospitals, as well as in data science and AI innovation. These strengths allow Bayer to conduct more efficient clinical trials and deliver medicines to patients faster.
A. Hager also noted the Chinese government's strong commitment to the foreign investment stabilization plan and new measures to establish free trade zones that allow foreign-invested enterprises to participate in research and development in gene and cell therapy, thereby facilitating opportunities for joint innovation.
Speaking about her first trip to China, A. Hager said what she saw was "very encouraging and inspiring." "There's genuine commitment here, as well as pragmatism," she noted.
"The fact that China is continuing this high-level openness policy is actually helping to create a dynamic and supportive ecosystem. And this is what truly makes us optimistic. It makes us believe that strengthening our community here and finding partners for collaboration is the right step," she said, adding that China is becoming a key force in the global pharmaceutical industry.
“That’s why we believe that if we really want to achieve scientific breakthroughs as a global pharmaceutical company, we need to have a strong position in China as well,” she told Xinhua.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.